MeiraGTx's Q2 2026 financials are dominated by a non-recurring $321.4M collaboration milestone, which temporarily transformed its income statement but does not reflect sustainable commercial operations. The company's core business continues to burn cash, with ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $1.71+473.1% vs -$0.46 | $321M+45819.1% vs $700,000 |
Q2 2026 May 14, 2026 | -$0.57-32.6% vs -$0.43 | $293,000-98.3% vs $17M |
Q2 2026 Mar 26, 2026 | $0.19+131.7% vs -$0.60 | $75M+5115.3% vs $1M |
Q4 2025 Nov 13, 2025 | -$0.62-24.0% vs -$0.50 | $410,000-89.4% vs $4M |
MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares MeiraGTx and
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Profitability This table compares Ascendis Pharma A/S and
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in S
Benchmark MGTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MeiraGTx Holdings plc (MGTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.79 | $999.26M | -7.60 | 144.57% | -140.31% | -368.19% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $1.02 | $345.89M | -4.43 | 8.83% | -1786.27% | — | — | |
| $2.62 | $402.07M | -1.46 | 25.39% | -157.32% | -196.63% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — |
MeiraGTx Holdings plc (MGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
MeiraGTx Holdings plc (MGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 7, 2026·SEC
Jun 15, 2026·SEC
Get notified when MGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MeiraGTx Holdings plc (MGTX) stock FAQ — growth, dividends, profitability & financials explained
MeiraGTx Holdings plc (MGTX) reported $397.5M in revenue for fiscal year 2025.
MeiraGTx Holdings plc (MGTX) grew revenue by 144.6% over the past year. This is strong growth.
Yes, MeiraGTx Holdings plc (MGTX) is profitable, generating $79.0M in net income for fiscal year 2025 (-140.3% net margin).
MeiraGTx Holdings plc (MGTX) has a return on equity (ROE) of -368.2%. Negative ROE indicates the company is unprofitable.
MeiraGTx Holdings plc (MGTX) generated $6.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
